Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

761
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
761
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

490
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
490
Liver Regeneration01:24

Liver Regeneration

4.8K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to Identify and Treat MetALD.

Gastroenterology & hepatology·2026
Same author

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia.

Alimentary pharmacology & therapeutics·2026
Same author

Evaluation of Abnormal Liver Biochemical Test Results.

Gastroenterology·2026
Same author

A systematic review of post-liver transplantation treatment and outcomes for late T-cell mediated, chronic ductopenic, and antibody-mediated rejection.

Hepatology communications·2026
Same author

International Expert Delphi Consensus on Endoscopic Ultrasound-guided Portosystemic Pressure Gradient: Best Practices and Future Directions.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

Gastroenterology·2025

Related Experiment Video

Updated: Mar 31, 2026

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

509

Regimens for Cirrhotic Patients.

Paul Y Kwo1

  • 1Gastroenterology/Hepatology Division, Liver Transplantation, Indiana University Health, Indiana University School of Medicine, 975 West Walnut, IB 327, Indianapolis, IN 46202-5121, USA.

Clinics in Liver Disease
|October 16, 2015
PubMed
Summary
This summary is machine-generated.

New direct-acting antiviral therapies offer over 90% sustained response rates for hepatitis C. However, patients with cirrhosis, especially those with genotypes 3, 4, and 6, still require optimized treatment strategies for optimal outcomes.

Keywords:
CirrhosisDirect-acting antiviralsHepatitis CLedipasvirOmbitasvirParitaprevirSimeprevirSofosbuvir

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Related Experiment Videos

Last Updated: Mar 31, 2026

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

509
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Direct-acting antiviral (DAA) agents have revolutionized hepatitis C virus (HCV) treatment.
  • Sustained virologic response (SVR) rates exceed 90% for most HCV genotypes.
  • Patients with cirrhosis represent a challenging population for achieving SVR.

Purpose of the Study:

  • To review current therapies for hepatitis C in patients with cirrhosis across all genotypes.
  • To identify gaps in data for specific genotypes (4, 6) in cirrhotic patients.
  • To propose management strategies for optimizing SVR in cirrhotic patients, particularly for genotype 3.

Main Methods:

  • Literature review of available direct-acting antiviral therapies for hepatitis C.
  • Analysis of treatment outcomes in patients with cirrhosis and varying HCV genotypes.
  • Synthesis of current evidence to suggest management approaches.

Main Results:

  • High SVR rates are achievable with DAAs, but challenges persist in cirrhotic patients.
  • Limited data exist for HCV genotypes 4 and 6 in patients with cirrhosis.
  • Genotype 3 patients with cirrhosis may require tailored strategies to match SVR rates of other genotypes.

Conclusions:

  • All-oral DAAs represent a significant advancement in hepatitis C therapy.
  • Further research and optimized strategies are needed for treating hepatitis C in patients with cirrhosis, especially for genotypes 3, 4, and 6.
  • Effective management of hepatitis C in cirrhotic patients is crucial for improving long-term outcomes.